Crescent Biopharma, Inc. (CBIO)
NASDAQ: CBIO · Real-Time Price · USD
14.91
+0.79 (5.59%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Crescent Biopharma Revenue
In the year 2025, Crescent Biopharma had annual revenue of $10.84M. That makes Crescent Biopharma the 36,501st largest company in the world by revenue and 4,799th in the United States.
Revenue (ttm)
$10.84M
Revenue Growth
n/a
P/S Ratio
53.70
Revenue / Employee
$172,217
Employees
69
Market Cap
638.16M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.84M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00K | -65.00K | -86.67% |
| Dec 31, 2022 | 75.00K | -1.08M | -93.53% |
| Dec 31, 2021 | 1.16M | -9.00M | -88.59% |
| Dec 31, 2020 | 10.16M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 18.50K | -20.05M | -99.91% |
| Dec 31, 2015 | 20.07M | 5.04M | 33.56% |
| Dec 31, 2014 | 15.03M | 11.03M | 276.37% |
| Dec 31, 2013 | 3.99M | -11.26M | -73.83% |
| Dec 31, 2012 | 15.26M | 11.44M | 300.04% |
| Dec 31, 2011 | 3.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| Phathom Pharmaceuticals | 239.66M |
| Zevra Therapeutics | 136.07M |
| DBV Technologies | 5.04M |
| Prime Medicine | 4.07M |
| Shattuck Labs | 1.00M |
| Silence Therapeutics | 615.00K |
CBIO News
- 3 days ago - Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewsWire
- 4 days ago - Crescent Biopharma upgraded to Buy from Neutral at H.C. Wainwright - TheFly
- 5 days ago - Crescent Biopharma announces FDA clearance of CR-002 IND application - TheFly
- 5 days ago - Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors - GlobeNewsWire
- 25 days ago - Crescent Biopharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - Crescent Biopharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 weeks ago - Crescent Biopharma to Present at September Investor Conferences - GlobeNewsWire
- 2 months ago - Crescent Biopharma reports Q2 EPS (74c), consensus (64c) - TheFly